Form 4: XBiotech Director MacAdam Granted Stock Options

Director Donald H. MacAdam was granted stock options to purchase 37,500 shares of XBiotech Inc. common stock on June 20, 2024.

Summary

• Donald H. MacAdam, a director of XBiotech Inc., was granted nonstatutory stock options on June 20, 2024.
• The options allow MacAdam to purchase 37,500 shares of XBiotech's common stock at an exercise price of $5.12 per share, which was the closing sales price on the grant date.
• The options vest in two equal portions, with the first half vesting six months from the grant date (December 20, 2024) and the second half vesting one year from the grant date.
• The options expire ten years from the grant date, on June 20, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine corporate action that aligns director interests with shareholders, which is generally viewed favorably.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. This grant is typical for director-level compensation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options as part of their compensation strategy to align executive incentives with shareholder value.
• The vesting schedule of six months and one year is relatively standard, as is the ten-year expiration period.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.

Key Dates